Cemadotin hydrochloride | CAS# 172837-41-1 (HCl) | tumours

MedKoo Cat#: 412556 | Name: Cemadotin hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cemadotin hydrochloride is the salt from of Cemadotin (free base), also known as, LU103793, a mitosis inhibitor potentially for the treatment of solid tumours. Cemadotin is also a synthetic derivative of Dolastatin 15, an antiproliferative compound which was isolated from the mollusk Dolabella auricularia. Like Dolastatin 15, LU103793 is highly cytotoxic in vitro (IC50 = 0.1 nM). LU103793 inhibits microtubule polymerization in a concentration-dependent manner (IC50 = 7 microM). Treatment with this compound also induced depolymerization of preassembled microtubules. Cell cycle analysis of tumor cell lines treated with LU103793 indicated a block in the G2-M phase.

Chemical Structure

Cemadotin hydrochloride

CAS#172837-41-1 (HCl)

Theoretical Analysis

MedKoo Cat#: 412556

Name: Cemadotin hydrochloride

CAS#: 172837-41-1 (HCl)

Chemical Formula: C35H57ClN6O5

Exact Mass: 676.4079

Molecular Weight: 677.33

Elemental Analysis: C, 62.07; H, 8.48; Cl, 5.23; N, 12.41; O, 11.81

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

159776-69-9 (free base) 172837-41-1 (HCl)

Synonym

Cemadotin hydrochloride; UNII-4LJQ1IXS6C

IUPAC/Chemical Name

(S)-N-benzyl-1-(N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl)pyrrolidine-2-carboxamide hydrochloride

InChi Key

MRJQTLJSMQOFTP-JGTKTWDESA-N

InChi Code

InChI=1S/C35H56N6O5.ClH/c1-22(2)28(37-32(43)29(23(3)4)38(7)8)34(45)39(9)30(24(5)6)35(46)41-20-14-18-27(41)33(44)40-19-13-17-26(40)31(42)36-21-25-15-11-10-12-16-25;/h10-12,15-16,22-24,26-30H,13-14,17-21H2,1-9H3,(H,36,42)(H,37,43);1H/t26-,27-,28-,29-,30-;/m0./s1

SMILES Code

CC([C@@H](C(N([C@H](C(N1CCC[C@H]1C(N2CCC[C@H]2C(NCc3ccccc3)=O)=O)=O)C(C)C)C)=O)NC([C@@H](N(C)C)C(C)C)=O)C.Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 677.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Jordan MA, Walker D, de Arruda M, Barlozzari T, Panda D. Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action. Biochemistry. 1998 Dec 15;37(50):17571-8. doi: 10.1021/bi9817414. PMID: 9860873. 2: Supko JG, Lynch TJ, Clark JW, Fram R, Allen LF, Velagapudi R, Kufe DW, Eder JP Jr. A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion. Cancer Chemother Pharmacol. 2000;46(4):319-28. doi: 10.1007/s002800000152. PMID: 11052630. 3: Mross K, Berdel WE, Fiebig HH, Velagapudi R, von Broen IM, Unger C. Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeitsgruppe Pharmakologie in der Onkologie und Haematologie (APOH) Group of the German Cancer Society. Ann Oncol. 1998 Dec;9(12):1323-30. doi: 10.1023/a:1008430515881. PMID: 9932163. 4: Jayakumar J, Anishetty S. Molecular Dynamics simulations of Inhibitor of Apoptosis Proteins and identification of potential small molecule inhibitors. Bioorg Med Chem Lett. 2014 May 1;24(9):2098-104. doi: 10.1016/j.bmcl.2014.03.046. Epub 2014 Mar 26. PMID: 24717152. 5: Bernardes GJ, Steiner M, Hartmann I, Neri D, Casi G. Site-specific chemical modification of antibody fragments using traceless cleavable linkers. Nat Protoc. 2013 Nov;8(11):2079-89. doi: 10.1038/nprot.2013.121. Epub 2013 Oct 3. PMID: 24091555. 6: Cruz-Monserrate Z, Mullaney JT, Harran PG, Pettit GR, Hamel E. Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography. Eur J Biochem. 2003 Sep;270(18):3822-8. doi: 10.1046/j.1432-1033.2003.03776.x. PMID: 12950266. 7: Bai R, Edler MC, Bonate PL, Copeland TD, Pettit GR, Ludueña RF, Hamel E. Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity. Mol Pharmacol. 2009 Jan;75(1):218-26. doi: 10.1124/mol.108.051110. Epub 2008 Oct 16. PMID: 18927208; PMCID: PMC2635573. 8: Lansiaux A, Bailly C. Les dolastatines [Dolastatins]. Bull Cancer. 1999 Nov;86(11):897-901. French. PMID: 10586105. 9: Zask A, Kaplan J, Musto S, Loganzo F. Hybrids of the hemiasterlin analogue taltobulin and the dolastatins are potent antimicrotubule agents. J Am Chem Soc. 2005 Dec 21;127(50):17667-71. doi: 10.1021/ja053663v. PMID: 16351096. 10: Rawat DS, Joshi MC, Joshi P, Atheaya H. Marine peptides and related compounds in clinical trial. Anticancer Agents Med Chem. 2006 Jan;6(1):33-40. doi: 10.2174/187152006774755519. PMID: 16475925.